High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis

Journal of Translational Medicine

Elif I. Aydinlar¹  Oreste Affatato²  Jessica Mwinyi²  Thiago C. Moulin²  Claudia Pisanu³  Victoria S. Babasieva⁴  Helgi B. Schiöth⁵  Vladimir N. Chubarev⁶  Vadim V. Tarasov⁷  Paola Torelli⁸  Marco Russo⁹ 

[1] Department of Neurology, Acibadem University School of Medicine, Istanbul, Turkey;Department of Neuroscience, University of Uppsala, Uppsala, Sweden;Department of Neuroscience, University of Uppsala, Uppsala, Sweden;Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy;Department of Neuroscience, University of Uppsala, Uppsala, Sweden;Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia;Department of Neuroscience, University of Uppsala, Uppsala, Sweden;Institute for Translational Medicine and Biothechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia;Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia;Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia;Institute for Translational Medicine and Biothechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia;Headache Centre, Department of Medicine and Surgery, University of Parma, Parma, Italy;Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Italy;

关键词: OnabotulinumtoxinA;    Botox;    Migraine;    Depression;    Meta-analysis;   

DOI  :  10.1186/s12967-021-02801-w

来源: Springer

【 授权许可】

CC BY